Search

Your search keyword '"Lee, Yeh Chen"' showing total 168 results
Start Over Author "Lee, Yeh Chen"
168 results on '"Lee, Yeh Chen"'

2. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease

Author

Giani, Claudia, Salawu, Abdulazeez, Ljevar, Silva, Denu, Ryan A., Napolitano, Andrea, Palmerini, Emanuela, Connolly, Elizabeth A., Ogura, Koichi, Wong, Daniel D., Scanferla, Roberto, Rosenbaum, Evan, Bajpai, Jyoti, Li, Zola Chia-Chen, Bae, Susie, D’Ambrosio, Lorenzo, Bialick, Steve, Wagner, Andrew J., Lee, Alexander T.J., Koseła-Paterczyk, Hanna, Baldi, Giacomo G., Brunello, Antonella, Lee, Yeh Chen, Loong, Herbert H., Boikos, Sosipatros, Campos, Fernando, Cicala, Carlo M., Maki, Robert G., Hindi, Nadia, Figura, Costanza, Almohsen, Shahd S., Patel, Sheyaskumar, Jones, Robin L., Ibrahim, Toni, Karim, Rooshdiya, Kawai, Akira, Carey-Smith, Richard, Boyle, Richard, Taverna, Silvia M., Lazar, Alexander J., Demicco, Elizabeth G., Bovee, Judith V.M.G., Dei Tos, Angelo P., Fletcher, Christopher, Baumhoer, Daniel, Sbaraglia, Marta, Schaefer, Inga-Marie, Miceli, Rosalba, Gronchi, Alessandro, and Stacchiotti, Silvia

Published
2025
Full Text
View/download PDF

4. Prognostic significance and accuracy of oncologists’ estimates of survival time in recurrent ovarian cancer

Author

Nahm, Sharon H., Kiely, Belinda E., O’Connell, Rachel L., Lee, Yeh Chen, Davis, Alison, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Berton, Dominique, Donnellan, Paul, Hilpert, Felix, Joly, Florence, Lanceley, Anne, Ledermann, Jonathan A., Okamoto, Aikou, Oza, Amit, Pignata, Sandro, Sehouli, Jalid, King, Madeleine T., Friedlander, Michael, Stockler, Martin R., and Roncolato, Felicia T.

Published
2025
Full Text
View/download PDF

5. How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes

Author

Haggstrom, Lucy, Lee, Yeh Chen, Scott, Clare, Harter, Philipp, Woelber, Linn, Ledermann, Jonathan, Gourley, Charlie, McNeish, Iain A, Amant, Frédéric, Ray-Coquard, Isabelle, Leary, Alexandra, Oza, Amit M, Tinker, Anna, González Martin, Antonio, Cecere, Sabrina Chiara, Pignata, Sandro, Colombo, Nicoletta, Yoshida, Hiroyuki, Marth, Christian, Rosengarten, Ora, Moore, Kathleen Nadine, Gómez-García, Eva María, Tan, David, and Friedlander, Michael L

Published
2024
Full Text
View/download PDF

6. Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry

Author

Lee, Yeh Chen, Whitely, Aleesha, Burling, Michael, Anderson, Lyndal, Cohen, Paul A., Naidoo, Mahendra, Richardson, Gary, Perera, Sharnel, Scott, Clare L., Friedlander, Michael, Brand, Alison, McNally, Orla, Hyde, Simon, Bunting, Michael, Jobling, Tom, Zalcberg, John, and Rome, Robert

Published
2025
Full Text
View/download PDF

7. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Zola, Paolo, Casanova, Claudia, Arcangeli, Valentina, Antonuzzo, Lorenzo, Gadducci, Angiolo, Cosio, Stefania, Clamp, Andrew, Persic, Mojca, McNeish, Ian, Tookman, Laura, Redondo Sanchez, Andrés, Choi, Chel Hun, Baldini, Editta, Palaia, Innocenza, Benedetti Panici, Pierluigi, Takahashi, Nobutaka, Lombard, Janine, Ardizzoia, Antonio, Bologna, Alessandra, Herrero Ibáñez, Ana Maria, Musolino, Antonino, Márquez Vázquez, Raúl, Pietzner, Klaus, Braicu, Elena, Heinzelmann-Schwarz, Viola A., Powell, Melanie, Yokoyama, Yoshihito, Baron-Hay, Sally, Abeni, Chiara, Martin Lorente, Cristina, Cueva, Juan Fernando, Trillsch, Fabian, Heitz, Florian, Ataseven, Beyhan, Petru, Edgar, Heubner, MartinLeonhard, Sadozye, Azmat Hassanq, Dubey, Sidharth, Tazbirkova, Andrea, Tiley, Susan, Chrystal, Kathryn, Kim, Sang Wun, Fehr, Mathias, Scatchard, Kate, Anand, Anjana, Taylor, Alexandra, Watary, Hidemichi, Enomoto, Takayuki, Yoshihara, Kosuke, Selva-Nayagam, Sudarsha, Karki, Bhaskar, Harrison, Michelle, Wilkinson, Kate, Goh, Jeffrey, Glasgow, Amanda, Chantrill, Lorraine, Lee, Chulmin, Bertolini, Alessandro, Narducci, Filomena, Bellotti, Giovanna, Fusco, Vittorio, Aebi, Stefan, Del Grande, Maria, Colombo, Ilaria, Tokunaga, Hideki, Shigeta, Shogo, Goss, Geraldine, Siow, Zhen Rong, Steer, Christopher, Lin, Hao, Lee, Kwang-Beom, Di Meglio, Giovanni, Massa, Elena, De Marino, Elvira, Tortora, Vincenzo, Palacio Vazquez, Isabel, Tsuji, Kosuke, Tominaga, Eiichiro, Black, Allison, So, Kyeong A, Suh, Dong Hoon, Lee, Keun Ho, Kim, Yong Man, Fossati, Roldano, Carlucci, Luciano, Barberis, Massimo, Torri, Valter, Santoni, Anna, Colombo, Nicoletta, Biagioli, Elena, Harano, Kenichi, Galli, Francesca, Hudson, Emma, Antill, Yoland, Rabaglio, Manuela, Marmé, Frederic, Marth, Christian, Parma, Gabriella, Fariñas-Madrid, Lorena, Nishio, Shin, Allan, Karen, Lee, Yeh Chen, Piovano, Elisa, Pardo, Beatriz, Nakagawa, Satoshi, McQueen, John, Zamagni, Claudio, Manso, Luis, Takehara, Kazuhiro, Tasca, Giulia, Ferrero, Annamaria, Tognon, Germana, Lissoni, Andrea Alberto, Petrella, Mariacristina, Laudani, Maria Elena, Rulli, Eliana, Uggeri, Sara, and Barretina Ginesta, M Pilar

Published
2024
Full Text
View/download PDF

8. Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

Author

Roncolato, Felicia, King, Madeleine T., O'Connell, Rachel L., Lee, Yeh Chen, Joly, Florence, Hilpert, Felix, Lanceley, Anne, Yoshida, Yoshio, Bryce, Jane, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Ledermann, Jonathan A., Berton, Dominique, Sehouli, Jalid, Kaminsky, Marie-Christine, Stockler, Martin R., and Friedlander, Michael

Published
2024
Full Text
View/download PDF

10. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Author

Campbell, Rachel, Costa, Daniel S.J., Stockler, Martin R., Lee, Yeh Chen, Ledermann, Jonathan A., Berton, Dominique, Sehouli, Jalid, Roncolato, Felicia T., Connell, Rachel O., Okamoto, Aikou, Bryce, Jane, Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Lanceley, Anne, Joly, Florence, Hilpert, Felix, Feeney, Amanda, Kaminsky, Marie C., Diamante, Katrina, Friedlander, Michael L., and King, Madeleine T.

Published
2022
Full Text
View/download PDF

11. Cell‐free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer.

Author

Werner, Bonnita, Powell, Elyse, Duggan, Jennifer, Cortesi, Marilisa, Lee, Yeh Chen, Arora, Vivek, Athavale, Ramanand, Dean, Michael, Warton, Kristina, and Ford, Caroline E.

Abstract

The emergence of targeted therapies has transformed ovarian cancer treatment. However, biomarker profiling for precision medicine is limited by access to quality, tumour‐enriched tissue samples. The use of cell‐free DNA (cfDNA) in ascites presents a potential solution to this challenge. In this study, next‐generation sequencing was performed on ascites‐derived cfDNA samples (26 samples from 15 human participants with ovarian cancer), with matched DNA from ascites‐derived tumour cells (n = 5) and archived formalin‐fixed paraffin‐embedded (FFPE) tissue (n = 5). Similar tumour purity and variant detection were achieved with cfDNA compared to FFPE and ascites cell DNA. Analysis of large‐scale genomic alterations, loss of heterozygosity and tumour mutation burden identified six cases of high genomic instability (including four with pathogenic BRCA1 and BRCA2 mutations). Copy number profiles and subclone prevalence changed between sequential ascites samples, particularly in a case where deletions and chromothripsis in Chr17p13.1 and Chr8q resulted in changes in clinically relevant TP53 and MYC variants over time. Ascites cfDNA identified clinically actionable information, concordant to tissue biopsies, enabling opportunistic molecular profiling. This advocates for analysis of ascites cfDNA in lieu of accessing tumour tissue via biopsy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand.

Author

Rajadevan, Niveditha, Flinkier, Ariane, Saunders, Hugo, Lee, Yeh Chen, Scott, Clare, Khaw, Pearly, Allan, Prue, Davies, Claire, Andrews, John, Wilson, Michelle, Lombard, Janine M, Harrison, Michelle, Nesfield, Heshani, DeFazio, Anna, Meniawy, Tarek, and Gorringe, Kylie L

Subjects
CONSENSUS (Social sciences), MEDICAL protocols, T-test (Statistics), MEDICAL specialties & specialists, RESEARCH funding, OVARIAN tumors, CANCER patient medical care, MEDICAL care, RESEARCH evaluation, QUESTIONNAIRES, FISHER exact test, ONCOLOGY, MANN Whitney U Test, WORK experience (Employment), DESCRIPTIVE statistics, CANCER chemotherapy, ATTITUDES of medical personnel, PRIORITY (Philosophy), TUMORS, DATA analysis software, MEDICAL practice
Abstract

Background: Mucinous ovarian carcinoma (MOC) is a rare ovarian cancer with limited evidence to support clinical care. Aims: We undertook a clinician survey to better understand current practice in treating MOC in Australia and New Zealand, and to determine any features associated with variation in care. In addition, we aimed to understand future research priorities. Methods: A RedCap survey was distributed to clinician members of the Australia New Zealand Gynaecological Oncology Group (ANZGOG). Questions included respondent demographics, three case studies and future research priorities. Clinicians were asked questions specific to their speciality. Results: Respondents (n = 47) were commonly experienced gynae‐oncology specialists, most often surgical (38%) or medical (30%) oncologists. There was good consensus for surgical approaches for stage I disease; however, variation in practice was noted for advanced or recurrent MOC. Variation was also observed for medical oncologists; in early‐stage disease there was no clear consensus on whether to offer chemotherapy, or which regimen to recommend. For advanced and recurrent disease a wide range of chemotherapy options was considered, with a trend away from an ovarian‐type toward gastrointestinal (GI)‐type regimens in advanced MOC. This practice was reflected in future research priorities, with 'Is a GI chemotherapy regimen better than an ovarian regimen?' the most highly ranked option, followed by 'Should stage 1C patients receive chemotherapy?' Conclusions: Although the number of respondents limited the analyses, it was clear that chemotherapy selection was a key point of divergence for medical oncologists. Future research is needed to establish well‐evidenced guidelines for clinical care of MOC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Author

Lee, Yeh Chen, King, Madeleine T, OʼConnell, Rachel L, Lanceley, Anne, Joly, Florence, Hilpert, Felix, Davis, Alison, Roncolato, Felicia T, Okamoto, Aikou, Bryce, Jane, Donnellan, Paul, Oza, Amit M, Avall-Lundqvist, Elisabeth, Berek, Jonathan S, Ledermann, Jonathan A, Berton, Dominique, Sehouli, Jalid, Feeney, Amanda, Kaminsky, Marie-Christine, Diamante, Katrina, Stockler, Martin R, and Friedlander, Michael L

Published
2022
Full Text
View/download PDF

22. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer

Author

Cohen, Paul A, Webb, Penelope M, King, Madeleine, Obermair, Andreas, Gebski, Val, Butow, Phyllis, Morton, Rachael, Lawson, Wanda, Yates, Patsy, Campbell, Rachel, Meniawy, Tarek, McMullen, Michelle, Dean, Andrew, Goh, Jeffrey, McNally, Orla, Mileshkin, Linda, Beale, Philip, Beach, Rhonda, Hill, Jane, Dixon, Cyril, Hegarty, Sue, Codde, Jim, Ives, Angela, Lee, Yeh Chen, Brand, Alison, Mellon, Anne, Bilic, Sanela, Black, Isobel, Jeffares, Stephanie, and Friedlander, Michael

Published
2022
Full Text
View/download PDF

24. PO003/#269 Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplification

Author

Au-Yeung, George, primary, Bressel, Mathias, additional, Prall, Owen, additional, Opar, Petra, additional, Andrews, John, additional, Mongta, Sally, additional, Lee, Yeh Chen, additional, Gao, Bo, additional, Meniawy, Tarek, additional, Baron-Hay, Sally, additional, Black, Allison, additional, Kichenadasse, Ganessan, additional, Ananda, Sumitra, additional, Fox, Peter, additional, Bowtell, David, additional, and Mileshkin, Linda, additional

Published
2023
Full Text
View/download PDF

27. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers

Author

Gonzalez-Ochoa, Eduardo, primary, Milosevic, Michael, additional, Corr, Bradley, additional, Abbruzzese, James L, additional, Girda, Eugenia, additional, Miller, Rachel W, additional, Croke, Jennifer, additional, Mackay, Helen, additional, Lee, Yeh Chen, additional, Bowering, Valerie, additional, Ramsahai, Janelle, additional, Wang, Lisa, additional, D'Souza, April, additional, Kunos, Charles A, additional, Oza, Amit M, additional, and Lheureux, Stephanie, additional

Published
2023
Full Text
View/download PDF

30. Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

Author

Pitiyarachchi, Omali, primary, Lee, Yeh Chen, additional, Sim, Hao-Wen, additional, Srirangan, Sivatharsny, additional, Mapagu, Cristina, additional, Kirk, Judy, additional, Harnett, Paul R., additional, Balleine, Rosemary L., additional, Bowtell, David D.L., additional, Samimi, Goli, additional, Brand, Alison H., additional, Marsh, Deborah J., additional, Beale, Philip, additional, Anderson, Lyndal, additional, Bouantoun, Natalie, additional, Provan, Pamela, additional, Ramus, Susan J., additional, DeFazio, Anna, additional, and Friedlander, Michael, additional

Published
2023
Full Text
View/download PDF

31. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

Author

Mileshkin, Linda R, primary, Moore, Kathleen N, additional, Barnes, Elizabeth H, additional, Gebski, Val, additional, Narayan, Kailash, additional, King, Madeleine T, additional, Bradshaw, Nathan, additional, Lee, Yeh Chen, additional, Diamante, Katrina, additional, Fyles, Anthony W, additional, Small, William, additional, Gaffney, David K, additional, Khaw, Pearly, additional, Brooks, Susan, additional, Thompson, J Spencer, additional, Huh, Warner K, additional, Mathews, Cara A, additional, Buck, Martin, additional, Suder, Aneta, additional, Lad, Thomas E, additional, Barani, Igor J, additional, Holschneider, Christine H, additional, Van Dyk, Sylvia, additional, Quinn, Michael, additional, Rischin, Danny, additional, Monk, Bradley J, additional, and Stockler, Martin R, additional

Published
2023
Full Text
View/download PDF

32. Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

Author

Campbell,Rachel, King,Madeleine T, Stockler,Martin R, Lee,Yeh Chen, Roncolato,Felicia T, Friedlander,Michael L, Campbell,Rachel, King,Madeleine T, Stockler,Martin R, Lee,Yeh Chen, Roncolato,Felicia T, and Friedlander,Michael L

Abstract

Rachel Campbell,1 Madeleine T King,1 Martin R Stockler,2 Yeh Chen Lee,2– 4 Felicia T Roncolato,2,5 Michael L Friedlander3,4 1University of Sydney, Faculty of Science, School of Psychology, Sydney, NSW, Australia; 2University of Sydney, NHMRC Clinical Trials Centre, Sydney, NSW, Australia; 3School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia; 4Department of Medical Oncology, Prince of Wales and Royal Hospital for Women, Sydney, NSW, Australia; 5MacArthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, NSW, AustraliaCorrespondence: Rachel Campbell, University of Sydney, Room 325, Brennan-Maccallum Building, Sydney, NSW, 2006, Australia, Tel +61 2 8627 7631, Email r.campbell@sydney.edu.auAbstract: Patient-reported outcomes (PROs) provide a valid, standardized way of assessing symptoms, adverse events and the subjective benefit of treatment from the patient’s perspective. Assessment of PROs is critical in ovarian cancer due to the high morbidity of the disease and its treatments. Several well-validated PRO measures are available to assess PROs in ovarian cancer. Their inclusion in clinical trials can provide evidence on the benefits and harms of new treatments based on patients’ experiences to guide improvements in clinical practice and health policy. Aggregate PRO data collected in clinical trials can be used to inform patients about likely treatment impacts and assist them to make informed treatment decisions. In clinical practice, PRO assessments can facilitate monitoring of a patient’s symptoms throughout treatment and follow-up to guide their clinical management; in this context, an individual patient’s responses can facilitate communication with their treating clinician about troublesome symptoms and their impact on their quality of life. This literature review aimed to provide clinicians and researchers with a better understanding of why and how PROs can be incorporated into ovarian ca

Published
2023

33. Supplementary Table from EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Author

Lheureux, Stephanie, primary, Oaknin, Ana, primary, Garg, Swati, primary, Bruce, Jeffrey P., primary, Madariaga, Ainhoa, primary, Dhani, Neesha C., primary, Bowering, Valerie, primary, White, Justin, primary, Accardi, Sarah, primary, Tan, Qian, primary, Braunstein, Marsela, primary, Karakasis, Katherine, primary, Cirlan, Iulia, primary, Pedersen, Stephanie, primary, Li, Tiantiam, primary, Fariñas-Madrid, Lorena, primary, Lee, Yeh Chen, primary, Liu, Zhihui (Amy), primary, Pugh, Trevor J., primary, and Oza, Amit M., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figures from EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Author

Lheureux, Stephanie, primary, Oaknin, Ana, primary, Garg, Swati, primary, Bruce, Jeffrey P., primary, Madariaga, Ainhoa, primary, Dhani, Neesha C., primary, Bowering, Valerie, primary, White, Justin, primary, Accardi, Sarah, primary, Tan, Qian, primary, Braunstein, Marsela, primary, Karakasis, Katherine, primary, Cirlan, Iulia, primary, Pedersen, Stephanie, primary, Li, Tiantiam, primary, Fariñas-Madrid, Lorena, primary, Lee, Yeh Chen, primary, Liu, Zhihui (Amy), primary, Pugh, Trevor J., primary, and Oza, Amit M., primary

Published
2023
Full Text
View/download PDF

35. Adjuvant Chemotherapy Following Chemo-Radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-Radiation Alone: The Randomised Phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)

Author

Mileshkin, Linda R., primary, Moore, Kathleen N., additional, Barnes, Elizabeth H., additional, Gebski, Val, additional, Narayan, Kailash, additional, King, Madeleine T., additional, Bradshaw, Nathan, additional, Lee, Yeh Chen, additional, Diamante, Katrina, additional, Fyles, Anthony W., additional, Small Jr., William, additional, Gaffney, David K., additional, Khaw, Pearly, additional, Brooks, Susan, additional, Thompson, J. Spencer, additional, Huh, Warner K., additional, Mathews, Cara A., additional, Buck, Martin, additional, Suder, Aneta, additional, Lad, Thomas E., additional, Barani, Igor J., additional, Holschneider, Christine H., additional, Van Dyk, Sylvia, additional, Quinn, Michael, additional, Rischin, Danny, additional, Monk, Bradley J., additional, and Stockler, Martin R., additional

Published
2023
Full Text
View/download PDF

36. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)

Author

Smith, Deborah, primary, Robledo, Kristy P., additional, Yip, Sonia, additional, Cummins, Michelle M., additional, Kok, Peey-Sei, additional, Lee, Yeh Chen, additional, Friedlander, Michael, additional, Baron-Hay, Sally, additional, Shannon, Catherine, additional, Coward, Jermaine, additional, Beale, Philip, additional, Goss, Geraldine, additional, Meniawy, Tarek, additional, Lombard, Janine, additional, Spurdle, Amanda B., additional, Andrews, John, additional, Stockler, Martin R., additional, Mileshkin, Linda, additional, and Antill, Yoland, additional

Published
2022
Full Text
View/download PDF

37. TP036/#426 Uplift (ENGOT-OV67/GOG-3048) a pivotal cohort of the XMT-1536–1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

Author

Richardson, Debra, primary, Perez Fidalgo, Jose Alejandro, additional, Gonzalez-Martin, Antonio, additional, Oaknin, Ana, additional, Hamilton, Erika, additional, Hays, John, additional, Pothuri, Bhavana, additional, Papadopoulos, Kyriakos, additional, Taylor, Sara, additional, Huang, Marilyn, additional, Lee, Yeh-Chen, additional, Krivak, Thomas, additional, Moreno-Garcia, Victor, additional, Calvo, Emiliano, additional, Randall, Leslie, additional, Starks, David, additional, Ross, Malcom, additional, Duska, Linda, additional, Gao, Bo, additional, Poka, Robert, additional, Putiri, Emily, additional, Barrett, Jamie, additional, Demars, Leslie, additional, and Concin, Nicole, additional

Published
2022
Full Text
View/download PDF

38. Management of Malignant Bowel Obstruction

Author

Jivraj, Nazlin, primary, Lee, Yeh Chen, additional, Tinker, Lisa, additional, Bowering, Valerie, additional, Ferguson, Sarah E., additional, Croke, Jennifer, additional, Karakasis, Katherine, additional, Chawla, Tanya, additional, Lau, Jenny, additional, Ng, Pamela, additional, Dhar, Preeti, additional, Shlomovitz, Eran, additional, Buchanan, Sarah, additional, Dhani, Neesha, additional, Oza, Amit M., additional, Stuart-McEwan, Terri, additional, and Lheureux, Stephanie, additional

Published
2022
Full Text
View/download PDF

40. IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.

Author

Au-Yeung, George, primary, Bressel, Mathias, additional, Prall, Owen, additional, Surace, Daniela, additional, Andrews, John, additional, Mongta, Sally, additional, Lee, Yeh Chen, additional, Gao, Bo, additional, Meniawy, Tarek, additional, Baron-Hay, Sally E., additional, Black, Allison Jane, additional, Kichenadasse, Ganessan, additional, Ananda, Sumitra, additional, Fox, Peter, additional, Bowtell, David, additional, and Mileshkin, Linda R., additional

Published
2022
Full Text
View/download PDF

41. Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).

Author

Mileshkin, Linda R., primary, Moore, Kathleen N., additional, Barnes, Elizabeth H, additional, Lee, Yeh Chen, additional, Gebski, Val, additional, Narayan, Kailash, additional, Bradshaw, Nathan, additional, Diamante, Katrina, additional, Fyles, Anthony W., additional, Small, William, additional, Gaffney, David K., additional, Khaw, Pearly, additional, Brooks, Susan, additional, Thompson, J Spencer, additional, Huh, Warner King, additional, Carlson, Matthew, additional, Robison, Katina, additional, Rischin, Danny, additional, Stockler, Martin R., additional, and Monk, Bradley J., additional

Published
2022
Full Text
View/download PDF

43. Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer.

Author

Jivraj, Nazlin, Lee, Yeh Chen, Tinker, Lisa, Bowering, Valerie, Ferguson, Sarah E., Croke, Jennifer, Karakasis, Katherine, Chawla, Tanya, Lau, Jenny, Ng, Pamela, Dhar, Preeti, Shlomovitz, Eran, Buchanan, Sarah, Dhani, Neesha, Oza, Amit M., Stuart-McEwan, Terri, and Lheureux, Stephanie

Subjects
ONCOLOGY nursing, BOWEL obstructions, OCCUPATIONAL roles, NURSING, OUTPATIENT medical care, SELF-management (Psychology), HEALTH care teams, HOSPITAL care, FEMALE reproductive organ tumors, CANCER patient medical care
Abstract

Background: Malignant bowel obstruction (MBO) in patients with advanced gynecologic cancer (GyCa) can negatively impact clinical outcomes and quality of life. Oncology nurses can support these patients with adequate tools/processes. Problem: Patients with GyCa with/at risk of MBO endure frequent emergency or hospital admissions, impacting patient care. Approach: Optimizing oncology nurses' role to improve care for patients with GyCa with/at risk of MBO, the gynecology oncology interprofessional team collaborated to develop a proactive outpatient nurse-led MBO model of care (MOC). Outcomes: The MBO MOC involves a risk-based algorithm engaging interdisciplinary care, utilizing standardized tools, risk-based assessment, management, and education for patients and nurses. The MOC has improved patient-reported confidence level of bowel self-management and decreased hospitalization. Following education, nurses demonstrated increased knowledge in MBO management. Conclusions: An outpatient nurse-led MBO MOC can improve patient care and may be extended to other cancer centers, fostering collaboration and best practice. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Author

Smith, Deborah, Robledo, Kristy P., Yip, Sonia, Cummins, Michelle M., Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Spurdle, Amanda B., Andrews, John, Stockler, Martin R., Mileshkin, Linda, and Antill, Yoland

Subjects
PROGRAMMED death-ligand 1, IMMUNE checkpoint inhibitors, STAINS & staining (Microscopy), IMMUNOHISTOCHEMISTRY, WOMEN, ENDOMETRIAL tumors, RESEARCH funding, RECEIVER operating characteristic curves, PROGRESSION-free survival, SENSITIVITY & specificity (Statistics), IMMUNOTHERAPY, OVERALL survival
Abstract

Simple Summary: Until recently the outcome for women with advanced endometrial carcinoma has been poor. New immune therapies have resulted in much better outcomes for some, but not all, women with advanced disease. Determining which women are likely to respond is important, both to identify potential responders and prevent overtreatment of women who are not likely to respond. In this study we looked to see if there were any other markers that could be used to better predict those tumors that would be more likely to respond to the immune therapy known as durvalumab versus those tumors more likely to be resistant. Using statistical methods to evaluate each of the components examined we determined the cut-off point with the best performance. We found that the presence of tumor associated inflammatory cells had the strongest association with response. We also found that an algorithm derived from our best performing cut-off points identified women not likely to respond to treatment. While the presence of inflammatory cells was not significant when mismatch repair status was considered, our novel algorithm was. This is a small study and the findings do require validation in a larger group of women. Women with advanced endometrial carcinoma (EC) with mismatch repair (MMR) deficiency have improved outcomes when treated with immune checkpoint inhibitors; however, additional biomarkers are needed to identify women most likely to respond. Scores for programmed death ligand 1 (PD-L1), immunohistochemical staining of tumor (TC+), immune cells (IC+) and presence of tumor-associated immune cells (ICP) on MMR deficient (n = 34) and proficient (n = 33) EC from women treated with durvalumab in the PHAEDRA trial (ANZGOG1601/CTC0144) (trial registration number ACTRN12617000106336, prospectively registered 19 January 2017) are reported and correlated with outcome. Receiver operating characteristic (ROC) analyses and area under the ROC curve were used to determine optimal cutpoints. Performance was compared with median cutpoints and two algorithms; a novel algorithm derived from optimal cutpoints (TC+ ≥ 1 or ICP ≥ 10 or IC+ ≥ 35) and the Ventana urothelial carcinoma (UC) algorithm (either TC+ ≥ 25, ICP > 1 and IC+ ≥ 25 or ICP = 1 and IC+ = 100). The cutpoint ICP ≥ 10 had highest sensitivity (53%) and specificity (82%), being prognostic for progression-free survival (PFS) (p = 0.01), while the optimal cutpoints algorithm was associated with overall survival (p = 0.02); these results were not significant after adjusting for MMR status. The optimal cutpoints algorithm identified non-responders (p = 0.02) with high sensitivity (88%) and negative predictive value (92%), remaining significant after adjustment for MMR. Although MMR status had the strongest association with response, further work to determine the significance of ICP ≥ 10 and the novel optimal cutpoint algorithm is needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer

Author

Cohen, Paul A, primary, Webb, Penelope M, additional, King, Madeleine, additional, Obermair, Andreas, additional, Gebski, Val, additional, Butow, Phyllis, additional, Morton, Rachael, additional, Lawson, Wanda, additional, Yates, Patsy, additional, Campbell, Rachel, additional, Meniawy, Tarek, additional, McMullen, Michelle, additional, Dean, Andrew, additional, Goh, Jeffrey, additional, McNally, Orla, additional, Mileshkin, Linda, additional, Beale, Philip, additional, Beach, Rhonda, additional, Hill, Jane, additional, Dixon, Cyril, additional, Hegarty, Sue, additional, Codde, Jim, additional, Ives, Angela, additional, Lee, Yeh Chen, additional, Brand, Alison, additional, Mellon, Anne, additional, Bilic, Sanela, additional, Black, Isobel, additional, Jeffares, Stephanie, additional, and Friedlander, Michael, additional

Published
2021
Full Text
View/download PDF

46. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

Author

Mileshkin, Linda R., primary, Moore, Kathleen N., additional, Barnes, Elizabeth, additional, Gebski, Val, additional, Narayan, Kailash, additional, Bradshaw, Nathan, additional, Lee, Yeh Chen, additional, Diamante, Katrina, additional, Fyles, Anthony W., additional, Small, William, additional, Gaffney, David K., additional, Khaw, Pearly, additional, Brooks, Susan, additional, Thompson, J Spencer, additional, Huh, Warner King, additional, Carlson, Matthew, additional, Mathews, Cara Amanda, additional, Rischin, Danny, additional, Stockler, Martin R., additional, and Monk, Bradley J., additional

Published
2021
Full Text
View/download PDF

47. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Author

Antill, Yoland, primary, Kok, Peey-Sei, additional, Robledo, Kristy, additional, Yip, Sonia, additional, Cummins, Michelle, additional, Smith, Deborah, additional, Spurdle, Amanda, additional, Barnes, Elizabeth, additional, Lee, Yeh Chen, additional, Friedlander, Michael, additional, Baron-Hay, Sally, additional, Shannon, Catherine, additional, Coward, Jermaine, additional, Beale, Philip, additional, Goss, Geraldine, additional, Meniawy, Tarek, additional, Lombard, Janine, additional, Andrews, John, additional, Stockler, Martin R, additional, and Mileshkin, Linda, additional

Published
2021
Full Text
View/download PDF

48. Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).

Author

Smith, Deborah, primary, Robledo, Kristy, additional, Yip, Sonia, additional, Cummins, Michelle, additional, Kok, Peey-Sei, additional, Lee, Yeh Chen, additional, Friedlander, Michael, additional, Baron-Hay, Sally E., additional, Shannon, Catherine M., additional, Coward, Jermaine, additional, Beale, Philip James, additional, Goss, Geraldine, additional, Meniawy, Tarek, additional, Lombard, Janine Margaret, additional, Spurdle, Amanda B., additional, Andrews, John, additional, Stockler, Martin R., additional, Mileshkin, Linda R., additional, and Antill, Yoland Catherine, additional

Published
2021
Full Text
View/download PDF

50. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

Author

Lheureux, Stephanie, primary, Oaknin, Ana, additional, Garg, Swati, additional, Bruce, Jeffrey P., additional, Madariaga, Ainhoa, additional, Dhani, Neesha C., additional, Bowering, Valerie, additional, White, Justin, additional, Accardi, Sarah, additional, Tan, Qian, additional, Braunstein, Marsela, additional, Karakasis, Katherine, additional, Cirlan, Iulia, additional, Pedersen, Stephanie, additional, Li, Tiantiam, additional, Fariñas-Madrid, Lorena, additional, Lee, Yeh Chen, additional, Liu, Zhihui (Amy), additional, Pugh, Trevor J., additional, and Oza, Amit M., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results